Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308772434> ?p ?o ?g. }
- W4308772434 endingPage "2424" @default.
- W4308772434 startingPage "2424" @default.
- W4308772434 abstract "Synthetic double-stranded small interfering RNAs (siRNAs) mimic interference RNAs (RNAi) and can bind target mRNAs with a high degree of specificity, leading to selective knockdown of the proteins they encode. However, siRNAs are very labile and must be both protected and transported by nanoparticles to be efficiently delivered into cells. In this work, we used a Janus-type polycationic amphiphilic β-cyclodextrin derivative to efficiently transfect siRNAs targeting mRNAs encoding mitogen-activated protein kinase (p42-MAPK) or Ras homolog enriched in brain (Rheb) into different cancer cell lines as well as astrocytes. We took advantage of this high transfection efficiency to simultaneously knock down p42-MAPK and Rheb to boost docetaxel (DTX)-mediated toxicity in two human prostate cancer cell lines (LNCaP and PC3). We found that double knockdown of p42-MAPK and Rheb increased DTX-toxicity in LNCaP but not in PC3 cells. However, we also observed the same effect when scramble siRNA was used, therefore pointing to an off-target effect. Indeed, we found that the siRNA we used in this work induced toll-like receptor 3 activation, leading to β-interferon production and caspase activation. We believe that this mechanism could be very useful as a general strategy to elicit an immune response against prostate cancer cells." @default.
- W4308772434 created "2022-11-15" @default.
- W4308772434 creator A5010963305 @default.
- W4308772434 creator A5025899580 @default.
- W4308772434 creator A5040298505 @default.
- W4308772434 creator A5040805937 @default.
- W4308772434 creator A5058310447 @default.
- W4308772434 creator A5061556072 @default.
- W4308772434 creator A5064939113 @default.
- W4308772434 creator A5088274147 @default.
- W4308772434 date "2022-11-09" @default.
- W4308772434 modified "2023-10-15" @default.
- W4308772434 title "A β-Cyclodextrin-Based Nanoparticle with Very High Transfection Efficiency Unveils siRNA-Activated TLR3 Responses in Human Prostate Cancer Cells" @default.
- W4308772434 cites W1556817153 @default.
- W4308772434 cites W1822930733 @default.
- W4308772434 cites W1832986140 @default.
- W4308772434 cites W1925248294 @default.
- W4308772434 cites W1981298152 @default.
- W4308772434 cites W2014356856 @default.
- W4308772434 cites W2021183708 @default.
- W4308772434 cites W2038660811 @default.
- W4308772434 cites W2039884471 @default.
- W4308772434 cites W2100932663 @default.
- W4308772434 cites W2104630342 @default.
- W4308772434 cites W2137467802 @default.
- W4308772434 cites W2140215797 @default.
- W4308772434 cites W2143026251 @default.
- W4308772434 cites W2150865892 @default.
- W4308772434 cites W2167279371 @default.
- W4308772434 cites W2188591882 @default.
- W4308772434 cites W2319391693 @default.
- W4308772434 cites W2483437652 @default.
- W4308772434 cites W2595177251 @default.
- W4308772434 cites W2598915810 @default.
- W4308772434 cites W2626539975 @default.
- W4308772434 cites W2735725998 @default.
- W4308772434 cites W2758568541 @default.
- W4308772434 cites W2786479496 @default.
- W4308772434 cites W2790013505 @default.
- W4308772434 cites W2810909862 @default.
- W4308772434 cites W2841858285 @default.
- W4308772434 cites W2916721669 @default.
- W4308772434 cites W2941388405 @default.
- W4308772434 cites W2943769781 @default.
- W4308772434 cites W2946912206 @default.
- W4308772434 cites W2982051641 @default.
- W4308772434 cites W2997813531 @default.
- W4308772434 cites W3000532606 @default.
- W4308772434 cites W3017292497 @default.
- W4308772434 cites W3024581224 @default.
- W4308772434 cites W3032478635 @default.
- W4308772434 cites W3033201788 @default.
- W4308772434 cites W3046354124 @default.
- W4308772434 cites W3048288662 @default.
- W4308772434 cites W3090689248 @default.
- W4308772434 cites W3091950240 @default.
- W4308772434 cites W3094145513 @default.
- W4308772434 cites W3111654639 @default.
- W4308772434 cites W3112067499 @default.
- W4308772434 cites W3148832547 @default.
- W4308772434 cites W3155516611 @default.
- W4308772434 cites W3188367623 @default.
- W4308772434 cites W3198093719 @default.
- W4308772434 cites W3203735032 @default.
- W4308772434 cites W3215449753 @default.
- W4308772434 cites W4221061854 @default.
- W4308772434 cites W4221071853 @default.
- W4308772434 cites W4224013200 @default.
- W4308772434 cites W4224433847 @default.
- W4308772434 cites W4280547163 @default.
- W4308772434 cites W4281553315 @default.
- W4308772434 cites W4281640467 @default.
- W4308772434 doi "https://doi.org/10.3390/pharmaceutics14112424" @default.
- W4308772434 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36365241" @default.
- W4308772434 hasPublicationYear "2022" @default.
- W4308772434 type Work @default.
- W4308772434 citedByCount "2" @default.
- W4308772434 countsByYear W43087724342023 @default.
- W4308772434 crossrefType "journal-article" @default.
- W4308772434 hasAuthorship W4308772434A5010963305 @default.
- W4308772434 hasAuthorship W4308772434A5025899580 @default.
- W4308772434 hasAuthorship W4308772434A5040298505 @default.
- W4308772434 hasAuthorship W4308772434A5040805937 @default.
- W4308772434 hasAuthorship W4308772434A5058310447 @default.
- W4308772434 hasAuthorship W4308772434A5061556072 @default.
- W4308772434 hasAuthorship W4308772434A5064939113 @default.
- W4308772434 hasAuthorship W4308772434A5088274147 @default.
- W4308772434 hasBestOaLocation W43087724341 @default.
- W4308772434 hasConcept C104317684 @default.
- W4308772434 hasConcept C121608353 @default.
- W4308772434 hasConcept C153911025 @default.
- W4308772434 hasConcept C166703698 @default.
- W4308772434 hasConcept C173396325 @default.
- W4308772434 hasConcept C184235292 @default.
- W4308772434 hasConcept C185592680 @default.
- W4308772434 hasConcept C190283241 @default.
- W4308772434 hasConcept C22615655 @default.
- W4308772434 hasConcept C2779723316 @default.